ACS chemical neuroscience molecule spotlight on STX209 (Arbaclofen)

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

STX209 (arbaclofen) is a γ-amino butyric acid type B (GABA B) receptor agonist from Seaside Therapeutics currently in clinical trials for autism spectrum disorders (ASD). The company has initiated a phase 2b study after positive results from a phase 2a trial, announced September 2010 (http://www.seasidetherapeutics.com/sites/default/files/STX209-ASD-P2b Trial-Initiation%206%2021%202011%20Final.pdf).

Original languageEnglish (US)
Number of pages1
JournalACS Chemical Neuroscience
Volume2
Issue number8
DOIs
StatePublished - Aug 17 2011

Fingerprint

GABA-B Receptor Agonists
Butyric Acid
Neurosciences
Molecules
Industry
Clinical Trials
Autism Spectrum Disorder
Therapeutics

Keywords

  • GABA
  • STX209
  • autism spectrum disorder (ASD)

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology

Cite this

ACS chemical neuroscience molecule spotlight on STX209 (Arbaclofen). / Hopkins, Corey R.

In: ACS Chemical Neuroscience, Vol. 2, No. 8, 17.08.2011.

Research output: Contribution to journalReview article

@article{3c96cf9b26d84fb5b44d1cad7b312c0d,
title = "ACS chemical neuroscience molecule spotlight on STX209 (Arbaclofen)",
abstract = "STX209 (arbaclofen) is a γ-amino butyric acid type B (GABA B) receptor agonist from Seaside Therapeutics currently in clinical trials for autism spectrum disorders (ASD). The company has initiated a phase 2b study after positive results from a phase 2a trial, announced September 2010 (http://www.seasidetherapeutics.com/sites/default/files/STX209-ASD-P2b Trial-Initiation{\%}206{\%}2021{\%}202011{\%}20Final.pdf).",
keywords = "GABA, STX209, autism spectrum disorder (ASD)",
author = "Hopkins, {Corey R.}",
year = "2011",
month = "8",
day = "17",
doi = "10.1021/cn200061g",
language = "English (US)",
volume = "2",
journal = "ACS Chemical Neuroscience",
issn = "1948-7193",
publisher = "American Chemical Society",
number = "8",

}

TY - JOUR

T1 - ACS chemical neuroscience molecule spotlight on STX209 (Arbaclofen)

AU - Hopkins, Corey R.

PY - 2011/8/17

Y1 - 2011/8/17

N2 - STX209 (arbaclofen) is a γ-amino butyric acid type B (GABA B) receptor agonist from Seaside Therapeutics currently in clinical trials for autism spectrum disorders (ASD). The company has initiated a phase 2b study after positive results from a phase 2a trial, announced September 2010 (http://www.seasidetherapeutics.com/sites/default/files/STX209-ASD-P2b Trial-Initiation%206%2021%202011%20Final.pdf).

AB - STX209 (arbaclofen) is a γ-amino butyric acid type B (GABA B) receptor agonist from Seaside Therapeutics currently in clinical trials for autism spectrum disorders (ASD). The company has initiated a phase 2b study after positive results from a phase 2a trial, announced September 2010 (http://www.seasidetherapeutics.com/sites/default/files/STX209-ASD-P2b Trial-Initiation%206%2021%202011%20Final.pdf).

KW - GABA

KW - STX209

KW - autism spectrum disorder (ASD)

UR - http://www.scopus.com/inward/record.url?scp=80051748528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051748528&partnerID=8YFLogxK

U2 - 10.1021/cn200061g

DO - 10.1021/cn200061g

M3 - Review article

C2 - 22860166

AN - SCOPUS:80051748528

VL - 2

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

SN - 1948-7193

IS - 8

ER -